A simple and cost-effective assay for measuring anti-drug antibody in human patients treated with Adalimumab.


It has been reported that 90% of the anti-drug antibody (ADA) to Adalimumab in human patients bound to the TNF-binding area, resulted in the annual loss of responses to Adalimumab up to 24%. It is of urgency to develop a cost-effective and easy-to-use ADA diagnostic kit for diagnosis of potential drug-resistance in patients treated with Adalimumab in clinic… (More)
DOI: 10.1016/j.jim.2017.10.003


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.